Armata Pharmaceuticals announces publication on phage Pa223

Armata Pharmaceuticals (ARMP) announced a paper in the Journal of Molecular Biology, JMB. The publication, titled, “High-resolution Cryo-EM Analysis of the Therapeutic Pseudomonas Phage Pa223,” describes the structure of phage Pa223, which is included in Armata’s five-phage clinical cocktail, AP-PA02. Armata is developing AP-PA02 as a potential treatment for chronic respiratory infections in people with cystic fibrosis and non-cystic fibrosis bronchiectasis. AP-PA02 has shown promising results in two Phase 2 clinical trials to date – SWARM-P.a. and Tailwind.